Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 563

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 563
---
 | -102% | ​ | ​ | ​ | ​                              | ​ |  7,559 | ​ | ​ | ​ | ​    | ​ | 21,004 | ​ | ​ | ​ | ​        | ​ | -64% | ​ | ​ |
| Total R&D expense                                 | ​ | ​ | ​                               | $ | 1,362 | ​ | ​ | ​ | ​    | $ | 25,451 | ​ | ​ | ​ | ​        | ​ | -95%  | ​ | ​ | ​ | ​                              | $ | 32,634 | ​ | ​ | ​ | ​    | $ | 80,095 | ​ | ​ | ​ | ​        | ​ | -59% | ​ | ​ |

For the three months ended September 30, 2024 compared to the three months ended September 30, 2023, the $16.1 million decrease in direct clinical trial costs and consultant services in support of clinical trials was primarily due to decreases related to the discontinuation of Cara’s oral difelikefalin atopic dermatitis program due to the clinical trial results announced in December 2023, the discontinuation of Cara’s oral difelikefalin program in advanced chronic kidney disease in January 2024, the discontinuation of Cara’s oral difelikefalin NP program due to the clinical trial results announced in June 2024, and decreases in supportive studies and other general costs associated with oral difelikefalin. The decrease in stock compensation expense is primarily related to the reductions in workforce in January 2024 and June 2024, as well as additional workforce reductions during the three months ended September 2024. The decrease in other R&D operating expenses for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was primarily related to decreases in payroll and related costs, travel costs and other related conference costs. For the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023, the $30.3 million decrease in direct clinical trial costs and consultant services in support of clinical trials was primarily due to decreases related to the discontinuation of Cara’s oral difelikefalin atopic dermatitis program due to the clinical trial results announced in December 2023, the discontinuation of Cara’s oral difelikefalin program in advanced chronic kidney disease in January 2024